Complete response to tremelimumab plus durvalumab treatment in hepatocellular carcinoma with a bile duct tumor thrombus:&nbsp;<br />A case report

Ishihara,Nobuaki; Komatsu,Shohei; Kido,Masahiro; Gon,Hidetoshi; Fukushima,Kenji; Urade,Takeshi; Yoshida,Toshihiko; Arai,Keisuke; Yanagimoto,Hiroaki; Toyama,Hirochika; Fukumoto,Takumi

doi:10.3892/ol.2024.14465

Complete response to tremelimumab plus durvalumab treatment in hepatocellular carcinoma with a bile duct tumor thrombus:
A case report

Authors:
- Nobuaki Ishihara
- Shohei Komatsu
- Masahiro Kido
- Hidetoshi Gon
- Kenji Fukushima
- Takeshi Urade
- Toshihiko Yoshida
- Keisuke Arai
- Hiroaki Yanagimoto
- Hirochika Toyama
- Takumi Fukumoto
View Affiliations

Affiliations: Department of Surgery, Division of Hepato‑Biliary‑Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe, Hyogo 650‑0017, Japan
Published online on: May 17, 2024 https://doi.org/10.3892/ol.2024.14465
Article Number: 332
Copyright: © Ishihara et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tremelimumab plus durvalumab (Dur/Tre) is the first‑line treatment for advanced hepatocellular carcinoma (HCC) worldwide. The present report describes the case of a 68‑year‑old man diagnosed with advanced HCC and a bile duct tumor thrombus (BDTT) who achieved a complete response to Dur/Tre therapy. The BDTT progressed to the bifurcation of the left and right hepatic ducts. Over time, both the tumors and BDTT progressively decreased in size, and a complete response was confirmed using the Response Evaluation Criteria in Solid Tumors (version 1.1.) 6 months after treatment administration. Subsequently, immune‑related adverse events, including type 1 diabetes mellitus and diabetic ketoacidosis, emerged, leading to treatment discontinuation. The patient was undergoing outpatient follow‑up in a drug‑free state with no signs of recurrence 290 days after the initial administration of Dur/Tre. Although long‑term and meticulous observations are required, the present findings could influence the choice of systemic chemotherapy for advanced HCC.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
2	Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, et al: Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 382:1894–1905. 2020. View Article : Google Scholar : PubMed/NCBI
3	Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Lim HY, Kudo M, Breder V, Merle P, et al: Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 76:862–873. 2022. View Article : Google Scholar : PubMed/NCBI
4	Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, Sukeepaisarnjaroen W, Kang YK, Dao TV, De Toni EN, et al: Tremelimumab plus durvalumab in unresected hepatocellular carcinoma. N Eng J Med Evid. 1:EVIDoa21000702022.
5	Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado A, Kelley RK, Galle PR, Mazzaferro V, Salem R, et al: BCLB strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 76:681–693. 2022. View Article : Google Scholar : PubMed/NCBI
6	Ikenaga N, Chijiwa K, Otani K, Ohuchida J, Uchiyama S and Kondo K: Clinicopathologic characteristics of hepatocellular carcinoma with bile duct invasion. J Gastrointest Surg. 13:492–497. 2009. View Article : Google Scholar : PubMed/NCBI
7	Wu JY, Sun JX, Wu JY, Huang XX, Bai YN, Wei YG, Zhang ZB, Zhou JY, Cheng SQ and Yan ML: Impact of bile duct tumor thrombus on the long-term surgical outcomes of hepatocellular carcinoma patients: A propensity score matching analysis. Ann Surg Oncol. 29:949–958. 2022. View Article : Google Scholar : PubMed/NCBI
8	Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N, Kubo S, Matsuyama Y, Nakashima O, Sakamoto M, et al: Validation and potential of albumin-bilirubin grade and prognostication in a nationwide survey of 46,681 hepatocellular carcinoma patients in Japan: The need for a more detailed evaluation of hepatic function. Liver Cancer. 6:325–36. 2017. View Article : Google Scholar : PubMed/NCBI
9	Eisenheauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1.). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
10	Kudo M, Aoki T, Ueshima K, Tsuchiya K, Morita M, Chishina H, Takita M, Hagiwara S, Minami Y, Ida H, et al: Achievement of complete response and drug-free status by atezolizumab plus bevacizumab combined with or without curative conversion in patients with transarterial chemoembolization-unsuitable, intermediate-stage hepatocellular carcinoma: A multicenter proof-of-concept study. Liver Cancer. 12:321–338. 2023. View Article : Google Scholar : PubMed/NCBI
11	Kelley RK, Sangro B, Harris W, Ikeda M, Okusaka T, Kang YK, Qin S, Tai DWM, Lim HY, Yau T, et al: Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: Randomized expansion of a phase I/II study. J Clin Oncol. 39:2991–3001. 2021. View Article : Google Scholar : PubMed/NCBI
12	Kudo M: Current therapeutic strategies for hepatocellular carcinoma in Japan. Liver Cancer. 12:497–509. 2023. View Article : Google Scholar : PubMed/NCBI
13	Kudo M: Scientific rationale for combined immunotherapy with PD-1/PD-L1 antibodies and VEGF inhibitors in advanced hepatocellular carcinoma. Cancers. 12:10892020. View Article : Google Scholar : PubMed/NCBI
14	Cho YK and Jung CH: Immune-checkpoint inhibitors-induced type 1 diabetes mellitus: From its molecular mechanisms to clinical practice. Diabetes Metab J. 47:757–766. 2023. View Article : Google Scholar : PubMed/NCBI
15	Johnson ML, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Laktionov K, Kim SW, Ursol G, Hussein M, Lim FL, et al: Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: The phase III POSEIDON study. J Clin Oncol. 41:1213–1227. 2023. View Article : Google Scholar : PubMed/NCBI
16	Yeh TS, Wang F, Chen TC, Yeh CN, Yu MC, Jan YY and Chen MF: Expression profile of microRNA-200 family in hepatocellular carcinoma with bile duct tumor thrombus. Ann Surg. 259:346–354. 2014. View Article : Google Scholar : PubMed/NCBI
17	Xu LB, Qin YF, Su L, Huang C, Xu Q, Zhang R, Shi XD, Sun R, Chen J, Song Z, et al: Cathepsin-facilitated invasion of BMI1-high hepatocellular carcinoma cells drives bile duct tumor thrombi formation. Nat Commun. 14:70332023. View Article : Google Scholar : PubMed/NCBI
18	Tanaka T, Kuzuya T, Ishigami M, Ito T, Ishizu Y, Honda T, Ishikawa T and Fujishiro M: Efficacy and safety of sorafenib in unresectable hepatocellular carcinoma with bile duct invasion. Oncology. 98:621–629. 2020. View Article : Google Scholar : PubMed/NCBI
19	Sho T, Suda G, Ogawa K, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Umemura M, Kawagishi N, Natsuizaka M, et al: Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria. Hepatol Res. 50:966–977. 2020. View Article : Google Scholar : PubMed/NCBI
20	Komatsu S, Fujishima Y, Kido M, Kuramitsu K, Goto T, Yanagimoto H, Toyama H and Fukumoto T: Significant response to atezolizumab plus bevacizumab treatment in unresectable hepatocellular carcinoma with portal vein tumor thrombus: A case report. BMC Gastroenterol. 21:4702021. View Article : Google Scholar : PubMed/NCBI
21	Kurisaki K, Soyama A, Hara T, Matsushima H, Imamura H, Tanaka T, Adachi T, Ito S, Kanetaka K, Hidaka M, et al: Pathologic complete response after chemotherapy with atezolizumab plus bevacizumab for hepatocellular carcinoma with tumor thrombus in the main portal trunk. Dig Surg. 40:84–89. 2023. View Article : Google Scholar : PubMed/NCBI